Marijuana for Symptoms of PTSD in U.S. Veterans Category: MAPS-Sponsored Medical Marijuana Research https://maps.org/research/mmj/marijuana-us/ Placebo-Controlled, Triple-Blind, Randomized Crossover Pilot Study of the Safety and Efficacy of Four Different Potencies of Smoked Marijuana in 76 Veterans with Chronic, Treatment-Resistant Posttraumatic Stress Disorder (PTSD) Site Principal Investigator: Sue Sisley, M.D. Coordinating Principal Investigator: Marcel Bonn-Miller, Ph.D. Co-Investigator: Paula Riggs, M.D. This study has completed enrollment. This study will explore whether smoked marijuana can help reduce PTSD symptoms in 76 U.S. veterans with chronic, treatment-resistant posttraumatic stress disorder (PTSD). Participants must be U.S. veterans, men or women, aged 18 or older with a diagnosis of PTSD that has not improved after [...]
Lire la suiteMedical Marijuana MAPS has completed the first-ever clinical trial of smoked marijuana for symptoms of posttraumatic stress disorder (PTSD) in veterans of war. https://maps.org/research/mmj MAPS is working to demonstrate the safety and efficacy of smoked botanical marijuana as a prescription medicine for specific medical uses to the satisfaction of the U.S. Food and Drug Administration. Our efforts to initiate medical marijuana research have been hindered by the National Institute on Drug Abuse (NIDA) and the Drug Enforcement Administration (DEA) since our founding in 1986. NIDA's previous monopoly on the supply of marijuana for research and the DEA's prior refusal to allow researchers to grow [...]
Lire la suiteAntidepressant-Like and Anxiolytic-Like Effects of Cannabidiol : A Chemical Compound of Cannabis sativa Alexandre R. de Mello Schier, Natalia P. de Oliveira Ribeiro, Danielle S. Coutinho, Sergio Machado, Oscar Arias-Carrión, José A. Crippa, Antonio W. Zuardi, Antonio E. Nardi and Adriana C. Silva CNS & Neurological Disorders - Drug Targets, 2014, 13, 953-960 Abstract : Anxiety and depression are pathologies that affect human beings in many aspects of life, including social life, productivity and health. Cannabidiol (CBD) is a constituent non-psychotomimetic of Cannabis sativa with great psychiatric potential, including uses as an antidepressant-like and anxiolytic-like compound. The aim of this study is to review [...]
Lire la suiteEffects of cannabidiol on brain excitation and inhibition systems; a randomised placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder Charlotte Marie Pretzsch, Jan Freyberg, Bogdan Voinescu, David Lythgoe, Jamie Horder, Maria Andreina Mendez, Robert Wichers, Laura Ajram, Glynis Ivin, Martin Heasman, Richard A. E. Edden, Steven Williams, Declan G. M. Murphy, Eileen Daly and Gráinne M. McAlonan Neuropsychopharmacology, 2019, 0, 1–8; https://doi.org/10.1038/s41386-019-0333-8 Abstract : There is increasing interest in the use of cannabis and its major non-intoxicating component cannabidiol (CBD) as a treatment for mental health and neurodevelopmental disorders, such as autism spectrum disorder (ASD). However, before [...]
Lire la suiteBibliographie : Cannabinoïdes et TSA/TED/psychoses infantiles. Dr Christian Sueur, GRECC, mars 2019. (2e version) ARAN A., CASSUTO H., LUBOTZKY : Cannabidiol Based Medical Cannabis in Children with Autism- a Retrospective Feasability Study (P3.318), Neurology Genetics, 2018, 90 (15). http://n.neurology.org/content/90/15_Supplement/P3.318 ARAN A., CASSUTO H., LUBOTZKY A., WATTAD N., HAZAN E. : Brief Report : Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems-A Retrospective Feasability Study, Journal of Autism and Developmental Disorders, 2018 Oct 31. Doi : 10.1007/s10803-018-3808-2 BARCHEL D., STOLAR O., De-HAAN T., ZIV-BARAN T., SABAN N., FUCHS D.O., KOREN G., BERKOVITCH M. : Oral Cannabidiol Use in Children With Auttism Spectrum Disorder to Treat Related Symptoms [...]
Lire la suiteMédicaments pour le traitement de la dépendance au cannabis Bibliothèque COCHRANE, 28 janvier 2019 Nielsen S, Gowing L, Sabioni P, Le Foll B https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008940.pub3/full/fr#CD008940-abs-0002 Contexte L'usage de cannabis est relativement courant et répandu mondialement. Dans la plupart des régions du monde, les usagers de cannabis sont en demande croissante de traitements. La tendance à la dépénalisation ou à la légalisation de l'usage du cannabis dans certains pays va probablement faire perdurer cette tendance. Actuellement, il n'existe pas de traitements spécifiques pour la consommation de cannabis. Cette revue visait à évaluer l'efficacité et l'innocuité des médicaments pour le traitement de la dépendance au cannabis. Date de la [...]
Lire la suiteTranslational Investigation of the Therapeutic Potential of Cannabidiol (CBD) : Toward a New Age José A. Crippa, Francisco S. Guimaraes, Alline C. Campos, Antonio W. Zuardi Frontiers in Immunology, 21 september 2018. https://doi.org/10.3389/fimmu.2018.02009 Background: Among the many cannabinoids in the cannabis plant, cannabidiol (CBD) is a compound that does not produce the typical subjective effects of marijuana. Objectives: The aim of the present review is to describe the main advances in the development of the experimental and clinical use of cannabidiol CBD in neuropsychiatry. Methods: A non-systematic search was performed for studies dealing with therapeutic applications of CBD, especially performed by Brazilian researchers. Results: CBD was shown [...]
Lire la suiteThe Endocannabinoid System and Cannabidiol’s Promise for the Treatment of Substance Use Disorder Yann Chye, Erynn Christensen, Nadia Solowij, and Murat Yücel Frontiers in Psychiatry, 19 February 2019, doi: 10.3389/fpsyt.2019.00063 Substance use disorder is characterized by repeated use of a substance, leading to clinically significant distress, making it a serious public health concern. The endocannabinoid system plays an important role in common neurobiological processes underlying substance use disorder, in particular by mediating the rewarding and motivational effects of substances and substance-related cues. In turn, a number of cannabinoid drugs (e.g., rimonabant, nabiximols) have been suggested for potential pharmacological treatment for substance dependence. Recently, cannabidiol [...]
Lire la suiteEndocannabinoid Signaling in Autism Bhismadev Chakrabarti, Antonio Persico, Natalia Battista, Mauro Maccarrone Neurotherapeutics, 2015, Volume 12, Issue 4, 837-847. DOI 10.1007/s13311-015-0371-9 Abstract Autism spectrum disorder (ASD) is a complex behavioral condition with onset during early childhood and a lifelong course in the vast majority of cases. To date, no behavioral, genetic, brain imaging, or electrophysiological test can specifically validate a clinical diagnosis of ASD. However, these medical procedures are often implemented in order to screen for syndromic forms of the disorder (i.e., autism comorbid with known medical conditions). In the last 25 years a good deal of information has been accumulated on the main components of [...]
Lire la suiteAutism Spectrum Disorder and Cannabidiol : Have We Seen This Movie Before? Carlos A. Salgado, and Daniel Castellanos, Glob Pediatr Health. 2018; 5: 2333794X18815412 doi: 10.1177/2333794X18815412 Received July 5, 2018. Received revised October 9, 2018. Accepted for publication October 23, 2018. Recently, the use of marijuana and cannabidiol (CBD) in children with autism spectrum disorder (ASD) has received increasing attention in the media with articles sensationally titled “Marijuana may be a miracle treatment for children with autism.” An absence of empirical data appears to have resulted in a growing body of anecdotal evidence espousing the benefits of CBD for children with ASD. Some reports describe the [...]
Lire la suite